Keyword: Lyrica

Pfizer totted up a list of accomplishments and milestones in 2018, besides the fact that it managed to eke out growth of about 2% for the year. It reorganized into three business units, for instance, reviving talk of an eventual generics spinoff and setting up its consumer health business for easier disposal.

Placeholder

Pharma companies do their best to fight off patent expirations and generic competition as long as possible to protect their big moneymakers. But this year looks like the end of the line for many of the industry's top brands.